Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Under the partnership, Alvotech will be responsible for commercial production at its new Reykjavik facility, where it will scale up and perform process validation.
Mark Levick, Alvotech’s chief executive officer, said in a statement that the partnership “marks an important milestone for our company as we work towards expanding our contract manufacturing business. We are pleased to be trusted with the responsibility of delivering high quality manufacturing services to Prestige Biopharma and look forward to further collaboration in the future. We pride ourselves on delivering highest quality commercial production from one of the best biopharma facilities in the world.”
The deal is the latest in a string of agreements related to biosimilars for Prestige, which in July entered into an exclusive agreement with Pharmapark LLC to supply and commercialize Prestige’s trastuzumab biosimilar, HD201, in Russia.
The Pharmapark deal came on the heels of an agreement with Mundipharma to license and supply the same biosimilar in parts of Europe.
In 2018, Prestige announced entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets, and even earlier, Prestige inked a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
In May of this year, the European Medicines Agency accepted for review a Marketing Authorization Application for HD201, and the company is also developing biosimilars referencing bevacizumab, adalimumab, denosumab, aflibercept, eculizumab, and ipilimumab.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.